Xeris Pharmaceuticals Inc. (XERS) Tops Q1 EPS by 3c; Offer Guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $33.2 million versus the consensus estimate of $30.96 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2023 revenue of $135-165 million, versus the consensus of $146.9 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Lucid reports Q2 output, names new CFO and five other leaders
• Tesla Q2 deliveries reach 480,126, topping estimates of 406,024
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations